• Séminaire vendredi 2 décembre 11h30 salles Multimédias

    vendredi 13 février 2015

    Le prochain séminaire médico-scientifique CRCL/CLB se tiendra le vendredi 2 décembre à 11h30 dans les salles Multimédias (Centre Léon Bérard, 2e étage). Nous sommes heureux d'accueillir Gabriel ICHIM (CRCL/LabEx DevWeCan) pour un séminaire intitulé : “Exploring the oncogenic role of apoptosis”.



    Informations scientifiques

    Informations scientifiques

    • ZEB1-mediated melanoma cell plasticity enhances resistance to MAPK inhibitors

      mardi 22 mars 2016
      This work involved the team of Alain Puisieux.
      Targeted therapies with MAPK inhibitors (MAPKi) are faced with severe problems of resistance in BRAF-mutant melanoma. In parallel to the acquisition of genetic mutations, melanoma cells may also adapt to the drugs through phenotype switching. The ZEB1 transcription factor, a known inducer of EMT and invasiveness, is now considered as a genuine oncogenic factor required for tumor initiation, cancer cell plasticity, and drug resistance in carcinomas. Here, we show that high levels of ZEB1 expression are associated with inherent resistance to MAPKi in BRAFV600-mutated cell lines and tumors.
      PubMed access: click here
    • Structural Decoding of the Netrin-1/UNC5 Interaction and its Therapeutical Implications in Cancers

      vendredi 25 mars 2016
      This study involves the team of Patrick Mehlen.
      Netrin-1 has been shown to be up-regulated in a fraction of human cancers as a mechanism to allow these tumors to escape the pro-apoptotic activity of some of its main dependence receptors, the UNC5 homologs (UNC5H). Here we identify the V-2 domain of netrin-1 to be important for its interaction with the Ig1/Ig2 domains of UNC5H2. We generate a humanized anti-netrin-1 antibody that disrupts the interaction between netrin-1 and UNC5H2 and triggers death of netrin-1-expressing tumor cells in vitro. We also present evidence that combining the anti-netrin-1 antibody with epidrugs such as decitabine could be effective in treating tumors showing no or modest netrin-1 expression. These results support that this antibody is a promising drug candidate.
      PubMed access: click here
    Offres d'emploi

    Offres d'emploi

    • Poste IE ou AI CDD

      mercredi 23 novembre 2016
      Un poste d'Ingénieur (ou assistant ingénieur) en techniques d’immuno-marquages est ouvert dans l'équipe « ciblage thérapeutique de la tumeur et de son environnement immunitaire »CDD de 6 mois renouvelable 12 mois. Pour plus d"infos : cliquez ici
    • 2-y postdoc position

      mercredi 23 novembre 2016

      A 2 year post-doctoral position is available in the Team Nuclear Domains and Pathologies to work on an ANR funded project on Pancreatic Cancer Research. More info: click here

    • CDD technicien plateforme d'immunomonitoring

      mercredi 9 novembre 2016
      Un CDD de technicien est disponible à la plateforme d'immuno-monitoring CRCL/CLB. pour plus d'infos cliquez ici
    • Postdoc position

      lundi 26 septembre 2016
      We are currently inviting applications from enthusiastic post-doctoral candidates to work on a European-funded project for an initial period of two years. More informations: click here
    • 2 postdoc positions

      mardi 13 septembre 2016
      Two postdoc positions are available in the lab of Franck Tirode. Details about the positions click here
    • Computational Biologist Position

      vendredi 8 avril 2016
      The team of C Caux and JY Blay is seeking a Computational Biologist to work within the team of Dr Christophe Caux at the Department of "Immunology, Virus, Inflammation" of the Cancer Research Center of Lyon (CRCL), France. More information : click here
    • Post-doctoral position open in Julien Marie's Lab

      mardi 29 mars 2016

      Dr.  Julien Marie lab is looking for a motivated post-doctoral candidate to study the effects of Transforming Growth Factor β on the regulation of T cell immune response.More information click here

    • Postdoc position in M. Gabut's team

      jeudi 16 avril 2015
      A full time post-doctoral fellow position in RNA-seq analysis is available in the M. Gabut team for a 3-year period. The objective of the project is to perform a comparative transcriptome analysis of cancer stem cells, normal stem cells and GBM tumors using next-generation sequencing (RNA-seq). For more information: click here